Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cardiff Oncology ( (CRDF) ) has provided an announcement.
On July 29, 2025, Cardiff Oncology announced positive data from its ongoing phase 2 clinical trial CRDF-004 for first-line RAS-mutated metastatic colorectal cancer, marking a significant milestone with the completion of patient enrollment. The company also reported positive results from an investigator-initiated trial of onvansertib in combination with paclitaxel for metastatic triple negative breast cancer, and announced a new patent issuance for the treatment of metastatic colorectal cancer. Financially, Cardiff Oncology reported $71 million in cash and investments as of June 30, 2025, with a projected cash runway into Q1 2027, despite increased operating expenses due to clinical trial costs and key hires.
The most recent analyst rating on (CRDF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.
Spark’s Take on CRDF Stock
According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.
Cardiff Oncology’s overall stock score reflects a mix of financial challenges and positive technical indicators. The company’s financial performance is a significant risk due to declining revenues and reliance on external financing. However, the stock’s technical outlook and recent corporate developments provide some optimism. The appointment of an experienced Chief Medical Officer and potential positive clinical trial data release are notable positives. The stock’s current P/E ratio and lack of dividend yield are valuation concerns, but the technical analysis and corporate events offer some balance to the overall assessment.
To see Spark’s full report on CRDF stock, click here.
More about Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition. Their lead asset, onvansertib, is being evaluated in combination with standard of care treatments for various cancers, including RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and metastatic triple negative breast cancer.
Average Trading Volume: 1,261,031
Technical Sentiment Signal: Buy
Current Market Cap: $248.1M
Learn more about CRDF stock on TipRanks’ Stock Analysis page.